PBMs made billions marking up specialty drugs by more than 1,000 percent: FTC
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through
FTC: Big 3 PBMs generated $7.3B from specialty generic drug markups
CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal Trade Commission (FTC) uncovered in its second interim staff report rele | The FTC released its second interim staff report Tuesday during Chair Lina Khan's final open commission meeting,
Big 3 PBMs reaped $7.3B from generic specialty drug markups: FTC
The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, OptumRx and Express Scripts.
FTC finds middlemen inflate specialty generic drug prices by billions of dollars
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs between 2017 and 2022,
FTC releases new findings in drug price inflation investigation
A new report from the Federal Trade Commission is uncovering what appears to be a major driver of the high cost of prescription drugs.
FTC: Pharmacy benefit managers inflated drug prices by $7.3B
WASHINGTON >> The nation’s three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including for heart disease, cancer and HIV, at their affiliated pharmacies,
FTC report finds pharmacy benefit managers hiked prices of generic drugs
A new report by the Federal Trade Commission says pharmacy benefit management companies are driving up your out-of-pocket costs for prescription drugs.
FTC says Minnesota-based Optum, et al., inflate cancer drug prices 1,000%
Optum RX, CVS Caremark and Express Scripts are marking up drugs that treat cancer and multiple sclerosis by more than 1,000-percent.
The FTC Finds United Health’s OptumRX Is Engaged In Widespread Price Gouging
The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...
pharmaphorum4d
FTC doubles down on PBM criticism in new report
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
MedCity News3d
Healthcare Leaders Support FTC’s Second Report on PBMs, While PBMs Criticize Findings
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
Top three insurers reaped $7.3 billion through their drug middlemen's markups, FTC says
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
Hosted on MSN3d
UnitedHealth's OptumRx Accused of Excessive Drug Pricing
The Federal Trade Commission accused UnitedHealth's OptumRx, CVS Caremark, and Cigna's Express Scripts of pocketing over $7 ...
Rolling Out2d
Troubling FTC probe reveals PBMs’ price-gouging tactics
Shocking revelations from a Federal Trade Commission, or FTC, investigation have exposed how three major prescription benefit managers, or PBMs, ...
Campus Safety Magazine3d
FTC: ‘Big 3’ Pharmacy Benefit Managers Engaged in Price Gouging
FTC: ‘Big 3’ Pharmacy Benefit Managers Engaged in Price Gouging, PBMs, UnitedHealth OptumRx, CVS Caremark Rx, Express Scripts ...
FOX 9 Minneapolis-St. Paul on MSN4d
FTC says Optum, other prescription benefit managers inflate cancer drug prices 1,000%
Prescription benefit managers have been under growing scrutiny from state and federal regulators who have accused them of ...
ConsumerAffairs4d
Another FTC report is highly critical of pharmacy benefit managers
In the debate over the high cost of prescription drugs, pharmacy benefit managers are hotly contested. PBMs, the middlemen in ...